Mounjaro vs Wegovy in the Philippines: Which GLP-1 Is Right for You?
- Christian Espedido
- May 12
- 9 min read
Two medications now dominate the conversation around medical weight management in the Philippines: Mounjaro and Wegovy. Both are weekly injectable medications. Both produce clinically meaningful weight loss. Both have generated enormous interest among Filipino patients, and both have generated an equal amount of confusion about which is the better choice.
The question of Mounjaro vs Wegovy Philippines is genuinely important because the two medications, while related, are not interchangeable. They work through different mechanisms, have different clinical trial outcomes, suit different patient profiles, and may be available at different price points and supply levels in the local market at any given time. The right answer for one person is not necessarily the right answer for another.
This guide offers a clear, clinically grounded comparison: what each medication is, how they differ, what the evidence says about their performance, and the specific factors a physician considers when recommending one over the other for a particular patient.
This article is for informational purposes only and does not constitute medical advice. Mounjaro and Wegovy are prescription medications in the Philippines. Always consult a licensed physician before starting any GLP-1 or tirzepatide-based weight management programme.
The Short Answer
For readers who want the verdict before the reasoning, here it is.
Mounjaro (tirzepatide) and Wegovy (semaglutide) are both excellent medical weight loss tools, but they are not equivalent. Mounjaro is a dual GIP and GLP-1 receptor agonist and consistently produces greater average weight loss in clinical trials. Wegovy is a GLP-1 single-agonist with a longer real-world safety track record.
Mounjaro tends to be the stronger first choice for patients with significant weight to lose, higher BMI, or notable insulin resistance. Wegovy remains an excellent option for patients with more modest goals, established response to GLP-1 therapy, or specific cost and access considerations.
Beyond that, the decision is genuinely individual. The sections below explain why, and how a physician at Jan Medical Group works through the question with each patient during the SHAPE programme consultation.
Understanding the Two Medications
How Wegovy Works
Wegovy is the brand name for semaglutide 2.4 mg, a higher-dose formulation of semaglutide developed specifically for chronic weight management by Novo Nordisk. The same molecule at a lower dose is sold as Ozempic for type 2 diabetes management.
Wegovy works as a GLP-1 receptor agonist, meaning it mimics the action of glucagon-like peptide-1, a naturally occurring gut hormone. This activation produces four effects: it signals fullness to the brain and reduces appetite, slows gastric emptying so the sensation of satiety lasts longer after meals, stimulates insulin secretion in response to elevated blood glucose, and reduces glucagon secretion, which helps lower fasting blood sugar levels.
The medication is administered via weekly subcutaneous self-injection, with dose titration starting at 0.25 mg weekly and increasing over sixteen to twenty weeks to the target dose of 2.4 mg weekly.
In the STEP-1 clinical trial, the landmark study for Wegovy's weight management indication, participants lost an average of approximately 15 percent of body weight over 68 weeks. This represented a significant advancement over earlier weight loss medications and established semaglutide as the clinical benchmark for non-surgical medical weight management. Because semaglutide has been in clinical use as Ozempic since 2017, the medication has an extensive real-world track record that gives both physicians and patients a well-documented understanding of its long-term safety and effectiveness.
How Mounjaro Works
Mounjaro is the brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It is the first medication of its class: a single molecule that activates two distinct gut hormone receptors at once.
The GLP-1 receptor activation produces the same effects as semaglutide. The added GIP receptor activation (glucose-dependent insulinotropic polypeptide) brings a second metabolic dimension, further enhancing insulin sensitivity, supporting fat metabolism in adipose tissue, and amplifying the appetite-reducing effects of GLP-1 activation through complementary neural pathways.
This dual mechanism is the pharmacological reason tirzepatide produces greater average weight loss than GLP-1 single-agonists in clinical trial data. In the SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of approximately 22.5 percent of body weight over 72 weeks, outcomes that begin to approach those seen with bariatric surgery.
Mounjaro is also administered as a weekly subcutaneous self-injection. Dose titration begins at 2.5 mg weekly and increases by 2.5 mg every four weeks, only when the patient is tolerating the current dose well, up to a maximum of 15 mg weekly.
The Clinical Comparison
Mechanism
Wegovy acts on the GLP-1 receptor only. Mounjaro acts on both GLP-1 and GIP receptors. This dual action is the fundamental pharmacological difference between the two medications and the primary driver of the differences in clinical outcomes observed in trials.
Weight Loss Efficacy
Clinical trial data consistently shows tirzepatide producing greater average weight loss than semaglutide. In the STEP-1 trial, Wegovy at 2.4 mg produced average weight loss of approximately 15 percent of body weight over 68 weeks. In the SURMOUNT-1 trial, Mounjaro at 15 mg produced average weight loss of approximately 22.5 percent of body weight over 72 weeks.
The most direct comparative evidence comes from the SURMOUNT-5 trial, a head-to-head study comparing tirzepatide against semaglutide 2.4 mg. SURMOUNT-5 showed tirzepatide producing approximately 47 percent greater weight loss than semaglutide. This is meaningful comparative data, though it does not change the fundamental principle that individual patient response varies considerably based on starting weight, metabolic profile, dietary adherence, and other factors. Some patients respond exceptionally well to semaglutide, while others find tirzepatide more tolerable or more effective for their particular profile.
Side Effects
Both medications share a similar side effect profile that reflects their shared GLP-1 mechanism. The most common experiences are nausea (particularly during dose escalation), vomiting, diarrhoea or constipation, reduced appetite and early satiety, and fatigue during the adjustment period. These effects are typically most pronounced during the first four to eight weeks and reduce significantly with proper dose titration.
Tirzepatide's additional GIP mechanism does not appear to add meaningfully to gastrointestinal side effect burden based on current trial data. Some patients actually report that tirzepatide is better tolerated than semaglutide, though this varies individually.
Both medications share the same core contraindications: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and a history of serious hypersensitivity reactions. Both require caution in patients with a history of pancreatitis.
Availability in the Philippines
As of 2026, both tirzepatide (Mounjaro) and semaglutide products are available in the Philippines through licensed medical channels, though supply availability may vary at any given time. Branded Mounjaro from Eli Lilly and branded Ozempic or Wegovy from Novo Nordisk should be sourced exclusively through licensed pharmaceutical suppliers, never from unverified online sources or grey-market channels. Your physician at Jan Medical Group will advise on current availability and the most appropriate option based on your clinical profile and the supply landscape at the time of your consultation.
Cost
Both medications represent a meaningful monthly investment. In the Philippines in 2026, semaglutide (Ozempic or Wegovy) typically ranges from PHP 8,000 to PHP 18,000 per month depending on dose, while tirzepatide (Mounjaro) typically ranges from PHP 12,000 to PHP 25,000 per month depending on dose.
These figures cover medication only. A comprehensive physician-supervised programme also includes consultation fees, body composition assessments, blood work, and monitoring appointments. All of these contribute to the total programme investment, and all of them are essential to safe and effective use.
Which One Is Right for You: The Six Factors That Decide
The choice between Mounjaro and Wegovy is a clinical decision, not a preference exercise. At Jan Medical Group, Dr. Jan Paolo P. Dipasupil works through six specific factors during the SHAPE programme consultation to determine which medication best fits a particular patient.
1. Amount of Weight to Lose and Metabolic Profile
For patients with significant weight to lose, particularly those with a BMI above 35 or with insulin resistance and elevated fasting glucose, tirzepatide's stronger efficacy data and dual metabolic mechanism may make it the more appropriate first choice. For patients with more modest weight loss goals, or those for whom the additional metabolic benefit of GIP activation is less clinically relevant, semaglutide remains an excellent and well-validated option.
2. Previous GLP-1 Experience
Patients who have previously used semaglutide (often as Ozempic) and experienced only partial response may benefit from tirzepatide's additional GIP mechanism. Patients who are entirely new to GLP-1 therapy and have no specific indication for the dual-agonist approach can reasonably start with semaglutide, given its longer real-world track record.
3. Tolerance and Side Effect History
Some patients tolerate one medication better than the other. This is not predictable in advance, but it can be managed through careful dose titration and regular monitoring. A patient who experienced significant gastrointestinal effects on a previous GLP-1 trial may benefit from a different titration approach, a different starting dose, or a switch to the alternative molecule.
4. Cardiovascular Considerations
Both medications have demonstrated cardiovascular benefits in trial data. Semaglutide showed cardiovascular outcome improvements in the SELECT trial (in non-diabetic overweight and obese patients), and tirzepatide showed similar benefits in the SURMOUNT-MMO trial. For patients with existing cardiovascular risk, the physician will assess which medication is more appropriate in the context of the full cardiac history and current treatment plan.
5. Cost and Sustainability
For some patients, the cost difference between tirzepatide and semaglutide is a meaningful practical consideration. A physician-supervised programme that a patient can sustain financially is safer and more effective than a theoretically superior programme that gets discontinued midway due to cost. Choosing the right medication includes choosing one the patient can stay on through the full active and maintenance phases.
6. Current Availability
Supply of specific medications and doses can fluctuate. The physician will factor current availability into the recommendation, ensuring that the programme can be continued consistently without interruption. Switching mid-programme due to supply gaps is possible but is best avoided where the initial choice can be made with continuity in mind.
What Both Medications Require: Physician Supervision
Whichever medication is more appropriate for your profile, Mounjaro and Wegovy share one absolute requirement: they must be used within a physician-supervised programme that includes proper medical evaluation, structured dose titration, and regular clinical monitoring.
The serious adverse events associated with these medications, documented internationally through FDA safety communications and incident reports, have consistently occurred in the context of unsupervised use. When either medication is obtained without a prescription, used without proper titration, or administered without physician oversight, the clinical safeguards that make these medications safe are removed entirely.
Physician supervision is not a bureaucratic formality. It is the clinical infrastructure that transforms a powerful medication into a safe and effective tool, and it is non-negotiable for either Mounjaro or Wegovy.
Frequently Asked Questions
What is the main difference between Mounjaro and Wegovy?
Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, producing stronger appetite suppression and greater average weight loss in clinical trials. Wegovy (semaglutide) activates GLP-1 only and has a longer real-world track record. Both are effective. The right choice depends on your individual health profile and physician assessment.
Which produces more weight loss?
Clinical trial data shows Mounjaro producing greater average weight loss, approximately 22.5 percent of body weight at the highest dose versus approximately 15 percent for Wegovy. Head-to-head trial data from SURMOUNT-5 showed tirzepatide producing approximately 47 percent greater weight loss than semaglutide 2.4 mg. Individual results vary considerably and should not be assumed from population averages.
Are both medications available in the Philippines in 2026?
Both tirzepatide (Mounjaro) and semaglutide products (Ozempic and Wegovy) are available in the Philippines through licensed medical channels, though supply availability may vary at any given time. Your physician at Jan Medical Group will advise on current availability during your consultation.
Can I switch from Wegovy to Mounjaro, or vice versa?
Yes. Switching between GLP-1 and dual GIP/GLP-1 medications is possible under physician supervision, with appropriate dose adjustment and monitoring. Your physician will guide this transition if it is clinically indicated based on your response to the initial medication.
Is one safer than the other?
Within a physician-supervised programme, both medications have well-established safety profiles. The contraindications are essentially the same for both. Semaglutide has the longer real-world track record because it has been in clinical use for diabetes management since 2017, while tirzepatide is newer but has a robust clinical trial dataset behind it.
How do I know which medication is right for me?
This is a clinical decision that requires a physician evaluation including body composition analysis, metabolic blood work, health history review, and goal assessment. At Jan Medical Group, the SHAPE programme consultation with Dr. Jan Paolo Dipasupil provides exactly this assessment, and the prescription decision follows from the clinical findings rather than a preference exercise.
Where can I begin the conversation in Metro Manila?
Jan Medical Group offers the SHAPE programme at its BGC branch (Park Triangle Mall, Taguig) and Quezon City branch (Bengar Building, Del Monte Avenue, Brgy. Manresa). A consultation with Dr. Jan Paolo Dipasupil is the first step.
How to Begin
Mounjaro and Wegovy are both genuinely powerful tools for medical weight management, and both represent real advances over what was available to Filipino patients even five years ago. The question of which is right for you cannot be answered by a comparison article alone, no matter how detailed. It requires a physician who knows your metabolic profile, your health history, your goals, and your circumstances.
The Mounjaro vs Wegovy Philippines conversation is best had during a proper consultation, not in a chat group or a marketing brochure. At Jan Medical Group, the SHAPE programme provides exactly that: a physician-led evaluation that produces a personalised recommendation, whether Mounjaro, Wegovy, or another approach altogether, based on clinical evidence and your individual profile. Not a trend. Not a preference. A medical decision made by a physician who remains accountable for your health throughout the entire programme.
If you are ready to have that conversation, a consultation at Jan Medical Group is where it begins.
Comments